|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.79 EUR | +0.84% |
|
+0.37% | +17.95% |
| 12-04 | Grifols achieves self-sufficiency in plasma-derived medicines in Egypt | RE |
| 12-03 | European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharma | 4.24B | 3.81B | 5.01B | 5.56B | 6.14B | |||||
Total Assets | 7.98B | 9.5B | 13.23B | 13.35B | 14.3B | |||||
CAPEX | -289M | -350M | - | - | - | |||||
D&A | 201M | 228M | 294M | 329M | 328M | |||||
Operating Income | 950M | 659M | 791M | 904M | 1.27B | |||||
Bio Supplies | 224M | 226M | 146M | 160M | 216M | |||||
Total Assets | 298M | 101M | 342M | 380M | 349M | |||||
CAPEX | -10.92M | -13.84M | - | - | - | |||||
D&A | 21.85M | 2.95M | 5.76M | 9.28M | 9.3M | |||||
Operating Income | 19.87M | 45.99M | 114M | 43.56M | 47.79M | |||||
Raw Materials and Others | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Medical Testing, Analyzing, and Diagnostic Equipment | ||||||||||
Diagnostic | 776M | 779M | 671M | 670M | 645M | |||||
Total Assets | 3.37B | 3.51B | 3.68B | 3.53B | 3.75B | |||||
CAPEX | -34.52M | -19.99M | - | - | - | |||||
D&A | 63.05M | 88.56M | 64.68M | 65.82M | 64.52M | |||||
Operating Income | 216M | 153M | 130M | 112M | 109M | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Others | 31.99M | 39.62M | 250M | 203M | 209M | |||||
Total Assets | 2.21B | 2.47B | 2.68B | 2.66B | 890M | |||||
CAPEX | -1.15M | -15.98M | - | - | - | |||||
D&A | 2.82M | 6.98M | 20.37M | 16.16M | 15.7M | |||||
Operating Income | 2.24M | -58.6M | -46.81M | 6.63M | 39.44M | |||||
D&A | 20.28M | 21.1M | 22.9M | 22.06M | 20.63M | |||||
CAPEX | -107M | -55.38M | - | - | - | |||||
Total Assets | 1.19B | 3.42B | 1.61B | 1.4B | 2.11B | |||||
Operating Income | -184M | -185M | -219M | -274M | -275M | |||||
Intersegments | -53.11M | -67.55M | -8.95M | - | - | |||||
Total Assets | -26.77M | -39.96M | -7M | - | - | |||||
Operating Income | 4.43M | -10.9M | 35.42M | 6.98M | - | |||||
Pharmaceutical Products | ||||||||||
Hospital | 119M | 141M | - | - | - | |||||
Total Assets | 257M | 269M | - | - | - | |||||
CAPEX | -11.55M | -12.62M | - | - | - | |||||
D&A | 12.44M | 12.06M | - | - | - | |||||
Operating Income | -12.5M | -7.74M | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States + Canada | 3.6B | 3.15B | 3.86B | 3.9B | 4.09B | |||||
Total Assets | 9.14B | 10.53B | 11.56B | 10.84B | 11.79B | |||||
CAPEX | -253M | -296M | - | - | - | |||||
Rest of the World | 906M | 872M | 1.18B | 1.44B | 1.58B | |||||
Total Assets | 2.09B | 2.22B | 2.22B | 2.24B | 396M | |||||
CAPEX | -14.27M | -9.76M | - | - | - | |||||
Rest of European Union | 495M | 544M | 712M | 893M | 1.12B | |||||
Total Assets | 2.93B | 5.39B | 6.6B | 7.05B | 7.58B | |||||
CAPEX | -92.87M | -91.39M | - | - | - | |||||
Spain | 339M | 362M | 321M | 363M | 423M | |||||
Total Assets | 1.12B | 1.09B | 1.16B | 1.19B | 1.64B | |||||
CAPEX | -93.79M | -71.02M | - | - | - | |||||
Unallocated Raw Material & Others | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Corporate | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Equities
- GRF Stock
- Financials Grifols, S.A.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















